Antares Pharma (NASDAQ:ATRS) Downgraded to Hold at BidaskClub

BidaskClub downgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a hold rating in a report released on Saturday morning, BidAskClub reports.

Separately, HC Wainwright lifted their price objective on shares of Cytokinetics from $21.00 to $26.00 and gave the stock a buy rating in a research note on Monday, May 6th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Antares Pharma presently has an average rating of Buy and a consensus price target of $4.83.

Shares of Antares Pharma stock opened at $3.04 on Friday. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $3.96. The company has a quick ratio of 1.90, a current ratio of 2.28 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $3.04. The firm has a market cap of $494.37 million, a PE ratio of -76.00 and a beta of 1.03.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The business had revenue of $23.29 million during the quarter, compared to analysts’ expectations of $17.46 million. On average, equities analysts forecast that Antares Pharma will post -0.1 EPS for the current year.

In other news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $2.67, for a total value of $80,100.00. Following the completion of the transaction, the director now directly owns 190,213 shares in the company, valued at approximately $507,868.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.49% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of ATRS. Corrado Advisors LLC acquired a new position in shares of Antares Pharma in the 2nd quarter valued at approximately $26,000. Alpine Woods Capital Investors LLC bought a new stake in shares of Antares Pharma during the 1st quarter valued at approximately $30,000. Enterprise Bank & Trust Co bought a new stake in shares of Antares Pharma during the 1st quarter valued at approximately $45,000. GSA Capital Partners LLP bought a new stake in shares of Antares Pharma during the 4th quarter valued at approximately $51,000. Finally, Amalgamated Bank bought a new stake in shares of Antares Pharma during the 4th quarter valued at approximately $59,000. Institutional investors own 42.99% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: What is the Bid-Ask Spread?

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.